ColoSTAT Beta kit verification and validation update
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Rhythm Biosciences Limited has announced the completion of verification and validation for the ColoSTAT Beta kit, confirming its performance for commercial application. The redesigned assay aims to simplify laboratory use, reduce turnaround times, and improve quality while lowering costs. The Beta kit is transitioning to final production stages, with plans for commercial availability following necessary accreditation.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Rhythm Biosciences Limited on 6ix
Earlier from Rhythm Biosciences
- Breast Cancer Risk Study University of Melbourne
- Quarterly Activities Report and Appendix 4C 31 March 2025
- EGM - Investor Presentation
- RHY Genetype Commercial Sales
- RHY Investor Webinar
Later from Rhythm Biosciences
- NATA Accreditation Awarded for Genetype Laboratory
- FY2025 R&D Tax Incentive Loan Funding
- Jun 25 Quarterly Activities Report and Appendix 4C
- ColoSTAT Kits Deliver Breakthrough Results
- Response to ASX Price Query
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences